arrow
A

Anna K.L. Reyners

university medical center groningen
H指数:36
被引数:4,254

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

EU JOINT ACTION: Integrating Palliative Care in the EU Cancer Agenda: Insights from JANE-2

欧盟联合行动:将姑息治疗纳入欧盟癌症议程:JANE-2的见解

2026-02-130
OAAI
Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer

Rimel, B.J.; Pujade-Lauraine, E.; Moore, K.; Pfisterer, J.; Han, S.; Cibula, D.; Reyners, A.; Redondo, A.; Papadimitriou, C.; Eitan, R.; 等. 评估聚(ADP-核糖)聚合酶抑制联合免疫疗法用于晚期卵巢癌一线治疗的III期临床试验. Oncologist 2025, 30, oyaf270. [Google Scholar] [CrossRef]

2025-10-011
OAAI
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel

质量调整的无疾病进展症状或治疗毒性的时间,在原发性晚期或复发性子宫内膜癌患者中使用dostarlimab联合卡铂-紫杉醇治疗与卡铂-紫杉醇治疗相比

2025-05-210
OA
APOLLO: neo-adjuvant pembrolizumab for primary vulvar squamous cell carcinoma—a multicenter, single-arm, phase II, clinical proof-of-concept study

APOLLO:原发性外阴鳞状细胞癌的新辅助帕博利珠单抗治疗——一项多中心、单臂、II期概念验证临床研究

2025-04-170
OAAI
Genome-Wide DNA Methylation and Copy Number Alterations in Gastrointestinal Stromal Tumors

胃肠道间质瘤的全基因组DNA甲基化和拷贝数改变

2025-03-010
OAAI
Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence

通过类似DRUG-Access Protocol (DAP)的平台解决临床价值的不确定性并改善新授权适应症的准入:真实世界证据的联合收集与评估

2024-09-010
PRE
Fear, anxiety and depression in gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study

荷兰胃肠道间质瘤 (GIST) 患者的恐惧,焦虑和抑郁: 来自横断面多中心研究的数据

2024-01-012
OAAI